Spondyloarthritis & psoriatic arthritis
Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2
Authors' conclusion
Upadacitinib 15 mg once daily demonstrated sustained efficacy and an acceptable safety profile in patients with PsA and exposure to one prior TNFi, irrespective of the duration of previous TNFi exposure.
Study context
- Population
- Patients with PsA and exposure to one prior tumour necrosis factor inhibitor (TNFi)
- Participants
- 195 patients
- Comparison
- Upadacitinib 15 mg once daily vs placebo
- Upadacitinib 15 mgn = 90
- Placebon = 105reference
Methodological detailsplacebo-controlled, placebo switched to upadacitinib at week 24
- Placebo-controlled
- Placebo switched to upadacitinib at week 24
Primary result
As reported in the abstract
week 24
Values · week 24
ACR50
ACR70
MDA
Further findings
Long-term responses · week 152
- Responses were maintained or improved through week 152
- Placebo switchers achieved sustained PASI75/90 responses across different anatomical regions
Efficacy by duration of prior TNFi exposure
- Generally similar regardless of duration of prior TNFi exposure in sensitivity and tertile analyses
Early pain as predictor of minimal disease activity (MDA) at week 152
- Lower pain scores at weeks 2 and 12 predicted MDA achievement at week 152
Safety
Treatment-emergent adverse events · week 152
- No new safety signals were identified
Original publication
Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2. RMD Open. Published 27 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →